Association of adiponectin with coronary heart disease and mortality: The Rancho Bernardo study

American Journal of Epidemiology

Volumn 165, Issue 2, 2007, Pages 164-174

  Laughlin, Gail A ^a   Barrett Connor, Elizabeth ^a   May, Susanne ^a   Langenberg, Claudia ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Adiponectin; Cardiovascular diseases; Coronary disease; Mortality

Indexed keywords

ADIPONECTIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

CARDIOVASCULAR DISEASE; DISEASE INCIDENCE; DISEASE PREVALENCE; EPIDEMIOLOGY; GLUCOSE; HEALTH MONITORING; HEALTH RISK; HORMONE; MORTALITY; STEROL;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONGESTIVE CARDIOMYOPATHY; DISEASE ASSOCIATION; FEMALE; GLUCOSE BLOOD LEVEL; HEART INFARCTION; HUMAN; INCIDENCE; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PREVALENCE; PROTEIN BLOOD LEVEL; SEX DIFFERENCE;

ADIPONECTIN; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CALIFORNIA; CORONARY DISEASE; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PREVALENCE; RADIOIMMUNOASSAY; RETROSPECTIVE STUDIES; RISK FACTORS; SEX FACTORS; SURVIVAL RATE;

NORTH AMERICA; UNITED STATES;

EID: 33846221186     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwk001     Document Type: Article

References (43)

1. Havel PJ. Update on adipocyte hormones: regulation of energy balance and carbohydrate/lipid metabolism. Diabetes 2004;53(suppl 1):S143-51.
2. Chandran M, Phillips SA, Ciaraldi T, et al. Adiponectin: more than just another fat cell hormone? Diabetes Care 2003;26:2442-50.
3. Kadowaki T, Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev 2005;26:439-51.
4. Cnop M, Havel PJ, Utzschneider KM, et al. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia 2003;46:459-69.
5. Kazumi T, Kawaguchi A, Sakai K, et al. Young men with highnormal blood pressure have lower serum adiponectin, smaller LDL size, and higher elevated heart rate than those with optimal blood pressure. Diabetes Care 2002;25:971-6.
6. Ryo M, Nakamura T, Kihara S, et al. Adiponectin as a biomarker of the metabolic syndrome. Circ J 2004;68:975-81.
7. Matsubara M, Maruoka S, Katayose S. Decreased plasma adiponectin concentrations in women with dyslipidemia. J Clin Endocrinol Metab 2002;87:2764-9.
8. Trujillo ME, Scherer PE. Adiponectin-journey from an adipocyte secretory protein to biomarker of the metabolic syndrome. J Intern Med 2005;257:167-75.
9. Hotta K, Funahashi T, Arita Y, et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000;20:1595-9.
10. Kumada M, Kihara S, Sumitsuji S, et al. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 2003;23:85-9.
11. Rothenbacher D, Brenner H, Marz W, et al. Adiponectin, risk of coronary heart disease and correlations with cardiovascular risk markers. Eur Heart J 2005;26:1640-6.
12. Yamauchi T, Hara K, Kubota N, et al. Dual roles of adiponectin/Acrp30 in vivo as an anti-diabetic and antiatherogenic adipokine. Curr Drug Targets Immune Endocr Metabol Disord 2003;3:243-54.
13. Koerner A, Kratzsch J, Kiess W. Adipocytokines: leptin-the classical, resistin-the controversial, adiponectin-the promising, and more to come. Best Pract Res Clin Endocrinol Metab 2005;19:525-46.
14. Pischon T, Girman CJ, Hotamisligil GS, et al. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 2004;291:1730-7.
15. Lindsay RS, Resnick HE, Zhu J, et al. Adiponectin and coronary heart disease: The Strong Heart Study. Arterioscler Thromb Vasc Biol 2005;25:e15-16.
16. Lawlor DA, Davey Smith G, Ebrahim S, et al. Plasma adiponectin levels are associated with insulin resistance, but do not predict future risk of coronary heart disease in women. J Clin Endocrinol Metab 2005;90:5677-83.
17. Dekker JM, Funahashi T, Nijpels G, et al. Adiponectin is associated with CVD risk profile but does not predict CVD mortality: The Hoorn Study. (Abstract 1437-P). Presented at the Annual Meeting of the American Diabetes Association, San Diego, California, June 10-14, 2005. (www.diabetes.org).
18. Laughlin GA, Barrett-Connor E, May S. Sex-specific determinants of serum adiponectin in older adults: the role of endogenous sex hormones. Int J Obes (advance online publication 4 July 2006); DOI: 10.1038/sj.ijo.0803427.
19. Wedick NM, Barrett-Connor E, Knoke JD, et al. The relationship between weight loss and all-cause mortality in older men and women with and without diabetes mellitus: The Rancho Bernardo Study. J Am Geriatr Soc 2002;50:1810-15.
20. Hypertension Detection and Follow-up Program Cooperative Group. The Hypertension Detection and Follow-up Program. Prev Med 1976;5:207-15.
21. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
22. Definition, diagnosis and classification of diabetes mellitus and its complications: report of a WHO consultation. Part 1: diagnosis and classification of diabetes mellitus. Geneva, Switzerland: World Health Organization, 1999.
23. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-421.
24. Hosmer DW, Lemeshow S. Applied logistic regression. New York, NY: John Wiley & Sons, Inc, 2000.
25. May S, Hosmer DW. A simplified method of calculating an overall goodness-of-fit test for the Cox proportional hazards model. Lifetime Data Anal 1998;4:109-20.
26. Kubota N, Terauchi Y, Yamauchi T, et al. Disruption of adiponectin causes insulin resistance and neointimal formation. J Biol Chem 2002;277:25863-6.
27. Maeda N, Shimomura I, Kishida K, et al. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 2002;8:731-7.
28. Schneider JG, von Eynatten M, Schiekofer S, et al. Low plasma adiponectin levels are associated with increased hepatic lipase activity in vivo. Diabetes Care 2005;28:2181-6.
29. Kato H, Kashiwagi H, Shiraga M, et al. Adiponectin acts as an endogenous antithrombotic factor. Arterioscler Thromb Vasc Biol 2006;26:224-30.
30. Wei EK, Giovannucci E, Fuchs CS, et al. Low plasma adiponectin levels and risk of colorectal cancer in men: a prospective study. J Natl Cancer Inst 2005;97:1688-94.
31. Ishikawa M, Kitayama J, Kazama S, et al. Plasma adiponectin and gastric cancer. Clin Cancer Res 2005;11:466-72.
32. Dal Maso L, Augustin LS, Karalis A, et al. Circulating adiponectin and endometrial cancer risk. J Clin Endocrinol Metab 2004;89:1160-3.
33. Mantzoros C, Petridou E, Dessypris N, et al. Adiponectin and breast cancer risk. J Clin Endocrinol Metab 2004;89:1102-7.
34. Kistorp C, Faber J, Galatius S, et al. Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation 2005;112:1756-62.
35. Kragelund C, Kober L, Flyvbjerg A, et al. Adiponectin predicts mortality in stable coronary heart disease. (Abstract 2763). Presented at the Scientific Sessions of the American Heart Association, Dallas, Texas, November 13-16, 2005. (www.americanheart.org).
36. Zoccali C, Mallamaci F, Tripepi G, et al. Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol 2002;13:134-41.
37. Efstathiou SP, Tsioulos DI, Tsiakou AG, et al. Plasma adiponectin levels and five-year survival after first-ever ischemic stroke. Stroke 2005;36:1915-19.
38. Ahima RS. Central actions of adipocyte hormones. Trends Endocrinol Metab 2005;16:307-13.
39. Qi Y, Takahashi N, Hileman SM, et al. Adiponectin acts in the brain to decrease body weight. Nat Med 2004;10:524-9.
40. Gavrila A, Peng CK, Chan JL, et al. Diurnal and ultradian dynamics of serum adiponectin in healthy men: comparison with leptin, circulating soluble leptin receptor, and cortisol patterns. J Clin Endocrinol Metab 2003;88:2838-43.
41. Shea SA, Hilton MF, Orlova C, et al. Independent circadian and sleep/wake regulation of adipokines and glucose in humans. J Clin Endocrinol Metab 2005;90:2537-44.
42. Yildiz BO, Suchard MA, Wong ML, et al. Alterations in the dynamics of circulating ghrelin, adiponectin, and leptin in human obesity. Proc Natl Acad Sci U S A 2004;101:10434-9.
43. Pischon T, Hotamisligil G, Rimm E. Adiponectin: stability in plasma over 36 hours and within-person variation over 1 year. Clin Chem 2003;49:650-2.